STK17A

Across TCGA pan-cancer cohorts, STK17A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of STK17A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where STK17A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types STK17A is over-expressed in tumor.

HNSC, CCRCC, and LUAD are the cancer types where STK17A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STK17A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	+0.653	<.001	11	view →
CCRCC	All	II,III,IV	+0.395	<.001	10	view →
LUAD	Female	All	+0.443	<.001	8	view →
LSCC	Female	All	+0.531	<.001	6	view →
PDAC	Male	All	+0.696	.021	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

STK17A–HNSC

Open the HNSC breakdown →